Our mission is clear: To build a breakthrough oncology company creating neoantigen-based therapeutics that significantly improve the lives of patients.

Neon Therapeutics is a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Genetic mutations, which are a hallmark of cancer, can result in specific immune targets called neoantigens. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy. By directing the immune system towards these targets, we believe our neoantigen-targeted therapies will offer a new level of patient and tumor specificity in the field of cancer immunotherapy that will drive a strong risk-benefit profile to dramatically improve patient outcomes.

We pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies. Our platform seeks to identify and harness the most therapeutically relevant neoantigens present within each patient’s tumor, and comprises three key elements that form an iterative feedback loop: our RECON Bioinformatics Engine; our deep capabilities in peptide chemistry and manufacturing; and our combined T cell biology and immune-monitoring expertise.

Our company builds on more than a decade of pioneering work by our world-class scientific founders across multiple leading global institutions including the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, MD Anderson Cancer Center, the Netherlands Cancer Institute and Washington University in St. Louis. Our founders were central to the development of both the fields of immuno-oncology and neoantigens and have published a number of seminal papers outlining the importance of neoantigens as critical immune targets for treating cancer.


Scientific Founders

James Allison, Ph.D.
MD Anderson Cancer Center
Ed Fritsch, Ph.D.
Founder-in-Residence, Neon Therapeutics
Nir Hacohen, Ph.D.
Broad Institute
Eric Lander, Ph.D.
Broad Institute
Robert Schreiber, Ph.D.
Washington University
Ton Schumacher, Ph.D.
Netherlands Cancer Institute
Catherine Wu, M.D.
Dana-Farber Cancer Institute

Board of Directors

Cary Pfeffer, M.D.
Chairman; Partner, Third Rock Ventures
Robert Kamen, Ph.D.
Entrepreneur-In-Residence, Third Rock Ventures
Eric Lander, Ph.D.
Founding Director, Broad Institute
Hugh O’Dowd, M.B.A.
Chief Executive Officer, Neon Therapeutics
Stephen Sherwin, M.D.
Clinical Professor of Medicine, University of California San Francisco
Robert Tepper, M.D.
Partner, Third Rock Ventures
Julian Adams, Ph.D.
Chairman & CEO, Gamida Cell
Meryl Zausner
Former Novartis executive

Scientific Advisors

Nina Bhardwaj, M.D., Ph.D.
Director of Immunotherapy, Professor of Medicine, Division of Hematology & Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Keith T. Flaherty, M.D.
Professor of Medicine, Harvard Medical School; Director, the Henri and Belinda Termeer Center for Targeted Therapy, Director of Clinical Research, Massachusetts General Hospital
John B. Haanen, M.D., Ph.D.
Head of Medical Oncology, Staff Scientist, Netherlands Cancer Institute; Professor, Leiden University Medical Centre
Roy S. Herbst, M.D., Ph.D.
Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Yale School of Medicine
Padmanee Sharma, M.D., Ph.D.
Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
Jedd Wolchok, M.D., Ph.D.
Chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center